TearLab Provides Updates on Its Osmolarity Test and TearLab Discoveryâ„¢ Platform

SAN DIEGO, Feb. 14, 2018 - TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced its plans to appeal a recent ruling from the Federal Court of Canada related to its single Canadian patent. TearLab initiated the lawsuit against I-Med Pharma and its i-Pen Osmolarity System in the Federal Court of Canada during February 2016. In the ruling published yesterday, the court found that the i-Pen did indeed infringe the TearLab patent; however, specific claims in the patent were deemed by the trial judge to be invalid. TearLab will appeal the finding of invalidity.

TearLab also reported that it has successfully passed the acceptance review phase with the U.S. Food and Drug Administration (FDA) for the clearance of its TearLab Discovery™ Platform, the Company’s next-generation in-vitro diagnostic testing system. The FDA will now progress to the substantive review of the filing. After securing FDA clearance, TearLab intends to pursue a CLIA waiver in an effort to prepare for commercialization in the US market. The Company has multiple additional patents beyond the single Canadian patent in the U.S. protecting the intellectual property around both osmolarity testing and the TearLab Discovery™ Platform. TearLab continues to prepare for the market introduction of the Discovery Platform, which the Company expects in the second half of 2018.

“Passing of the FDA acceptance review is an important milestone in the clearance process for the TearLab Discovery™ Platform. We are pleased to have progressed to the substantive review phase and look forward to advancing our development program,” said Seph Jensen, TearLab’s Chief Executive Officer.

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the OTCQB Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.